Essai clinique NCT05086692 · Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous

Essai clinique NCT05086692 (phase I/II) est «actif (non en recrutement)» sur ClinicalTrials.gov.

Pathologie: Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous · Interventions enregistrées: MDNA11, Pembrolizumab (KEYTRUDA®) · Dates enregistrées (source): 2021-08-27, 2028-10-20, 2021-10-21, 2026-10-30.

Résumé de l’étude (source : ClinicalTrials.gov, texte original en anglais):

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

Source: https://clinicaltrials.gov/study/NCT05086692